Nuron Biotech acquires meningitidis vaccine from Pfizer

Nuron Biotech, Inc., an Exton, Pennsylvania-based biologics and vaccines company, announced the acquisition of a vaccine for the prevention of disease caused by Neisseria meningitidis serogroup C on Monday.

Meningitec is a preservative free vaccine registered in 23 countries around the world. The vaccine protects against N. meningitidis, a major worldwide cause of infectious disease with most cases occurring in children.

"Meningitec is a tremendous opportunity to expand Nuron Biotech's portfolio with a commercially successful vaccine with an established market," Nuron Biotech CEO Shankar Musunuri said. "The addition of Meningitec represents an important milestone toward bringing innovative biologics and vaccines to patients with unmet needs around the world. Vaccines such as Meningitec and HibTITER have established track records in the prevention of infectious disease, and we are excited to see such high quality life-saving products in our portfolio."

Nuron Biotech plans to work closely with Pfizer to make sure there is a seamless transition and to continue the availability of Meningitec to patients in need.

"We are planning to expand into markets with unvaccinated and under-vaccinated populations, helping us address public health needs around the world," Richard C. Dinovitz, the vice president of marketing and business development at Nuron Biotech, said. "Meningitec is a proven, life-saving, preventative vaccine. In the early 2000s, Meningitec played a pioneering role in reducing disease caused by N. meningitidis serogroup C by 93 percent in children in the U.K."

N. meningitidis is estimated to cause 500,000 cases of disease worldwide each year with a 10 to 20 percent fatality rate. Without treatment, the disease has an up to a 90 percent fatality rate.